abbvie-biogen-and-pfizer-create-world-s-largest-resource-linking-rare-protein-coding-genetic-variants-to-human-health-and-disease

AbbVie, Biogen and Pfizer create world's largest resource linking rare protein-coding genetic variants to human health and disease

AbbVie, Biogen and Pfizer create world's largest resource linking rare protein-coding genetic variants to human health and disease

Managed by the Broad Institute of MIT and Harvard, the browser gives access to results from analyses of whole-exome sequencing data from 300,000 UK Biobank research participants

The access to the world's largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence analysis collaboration between AbbVie (NYSE: ABBV), Biogen Inc. (Nasdaq: BIIB) and Pfizer (NYSE: PFE). Managed by the Broad Institute of MIT and Harvard, the browser gives access to results from analyses of whole-exome sequencing data from 300,000 UK Biobank research participants. These genetic data have been paired with detailed health information to create this browsable resource.

The collaboration between AbbVie, Biogen and Pfizer to make these data available highlights the importance of working together to advance science. The companies engaged with the Broad Institute for data processing and to conduct single variant and gene-based association testing with nearly 4,000 UK Biobank phenotypes to identify associations between distinct genes or genetic variants and disease. In line with the collaboration members' commitment to openness, these results can now be accessed freely via the new browser. This browser will enable scientists worldwide to explore and utilize the data for their respective areas of interest in accordance with UK Biobank's terms of use.

"Human genetics has been foundational to understanding disease etiologies and is a first step to finding solutions to some of humanity’s most devastating diseases," said Professor Sir Rory Collins, UK Biobank Principal Investigator and Chief Executive. "Our hope is that this information will allow researchers to better understand the human genome and identify therapeutic strategies that can specifically target the underlying causes of disease." "We are proud to be involved in this exciting project and believe the collected information will yield important insights for the global scientific community," said Anthony Philippakis, Chief Data Officer at the Broad Institute. "By combining the expertise of the healthcare industry and the non-profit research community, we can carefully assess how biomedical data at this unprecedented scale is best utilized and hopefully accelerate the path from genetic discoveries towards novel therapeutics."

The UK Biobank whole-exome sequencing data has been generated as part of the UK Biobank Exome Sequencing Consortium, formed in 2018, which, in addition to AbbVie, Biogen, and Pfizer, includes additional industry partners, supporting a trend across the industry to collaborate in a precompetitive manner for generating the source data for an improved understanding of human biology and disease. The browser can be accessed via genebass.org.

 

AbbVie, Biogen and Pfizer create world's largest resource linking rare protein-coding genetic variants to human health and disease

We use our own and third-party cookies to enable and improve your browsing experience on our website. If you go on surfing, we will consider you accepting its use.